14.11.2024  16:30:07 Zm. - Wolumen Bid17:30:00 Ask17:30:00 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
461,30EUR - 66
Obrót: 26 080,60
-Wolumen Bid: - -Wolumen Ask: - 113,92 mldEUR - -

Opis działalności

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
 

Zarząd & Rada nadzorcza

CEO
Reshma Kewalramani, M.D.
Zarząd
Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D.
Rada nadzorcza
Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay
 

Dane firmy

Nazwa: Vertex Pharmaceuticals Inc.
Adres: 50 Northern Avenue,Boston, Massachusetts 02210, USA
Telefon: +1-617-961-7163
Fax: -
E-mail: Investorinfo@VRTX.com
Internet: www.vrtx.com/
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: 82,70%
Data IPO: 24.07.1991

Relacje inwestorskie

Nazwa: Susie Lisa
Telefon: +1-617-341-6108
Fax: -
E-mail: investorinfo@vrtx.com

Główni akcjonariusze

Inne
 
53,31%
Vanguard Group
 
8,63%
BlackRock Inc.
 
8,48%
Capital World Investors
 
8,45%
FMR LLC.
 
5,03%
State Street Corporation
 
4,68%
ALLIANCEBERNSTEIN L P
 
2,73%
PRICE T ROWE ASSOCIATES INC MD
 
2,28%
GEODE CAPITAL MANAGEMENT LLC
 
2,20%
Inne
 
4,21%